approved medicines as of june 5 2015_signed

2
 Building 1, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila Trunk Line 651-7800 Direct Line: 711-9501 Fax: 743-1829; 743-1786 URL: http://www.doh.gov.ph ; e-mail: [email protected]  Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY As of 05 June 2015, the Formulary Executive Council has recommended the INCLUSION of the following medicines in the Philippine National Formulary: Medicine Indication 1. Inactivated Poliomyelitis Vaccine (Type 1, 2 and 3) suspension for injection (IM/SC) Prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination 2. Etonogestrel implant 68 mg subdermal implant Hormonal contraceptive Interested parties may submit their comments or request for reconsideration on or before 24 July 2015. Otherwise, appeals will no longer be entertained after t he prescribed deadline.  ANNA MELISSA S. GUERRERO, MD, MPH (HTA) Division Chief  Pharmaceutical Division Office for Policy and Health Systems 

Upload: azuredream

Post on 04-Nov-2015

213 views

Category:

Documents


0 download

DESCRIPTION

policy

TRANSCRIPT

  • Building 1, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila Trunk Line 651-7800 Direct Line: 711-9501 Fax: 743-1829; 743-1786 URL: http://www.doh.gov.ph; e-mail: [email protected]

    Republic of the Philippines

    DEPARTMENT OF HEALTH

    OFFICE OF THE SECRETARY

    As of 05 June 2015, the Formulary Executive Council has recommended the INCLUSION of

    the following medicines in the Philippine National Formulary:

    Medicine Indication

    1. Inactivated Poliomyelitis Vaccine

    (Type 1, 2 and 3) suspension for

    injection (IM/SC)

    Prevention of poliomyelitis in infants,

    children and adults, for primary and booster

    vaccination

    2. Etonogestrel implant 68 mg

    subdermal implant

    Hormonal contraceptive

    Interested parties may submit their comments or request for reconsideration on or before 24

    July 2015. Otherwise, appeals will no longer be entertained after the prescribed deadline.

    ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

    Division Chief

    Pharmaceutical Division

    Office for Policy and Health Systems